"The Lenexa Ophthalmologists at Retina Associates, LLC specialize in the diagnosis and treatment of macular degeneration, diabetic retinopathy, retinal detachments, and more. Retina Associates, LLC is one of the most well-established and advanced practices devoted to diagnosing and treating diseases of the retina, macula, and vitreous among families in the Greater Kansas City area and the surrounding communities. To schedule an appointment at any of our offices serving Lenexa, Overland Park, Kansas City and other neighboring communities, send us a message or call our office!"

During the past decade, Retina Associates, P.A. conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 8 clinical trials were completed, i.e. on average, 114.3% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 6 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associates, P.A." #1 collaborator was "National Eye Institute (NEI)" with 5 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associates, P.A." are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (2 trials), "Geographic Atrophy" (2 trials), "Proliferative Diabetic Retinopathy" (1 trials) and "Vitreous Hemorrhage" (1 trials). Many other conditions were trialed in "Retina Associates, P.A." in a lesser frequency.

Most popular intervention types in "Retina Associates, P.A." are "Drug" (9 trials), "Procedure" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Lampalizumab" (2 trials), "Prompt aflibercept" (2 trials) and "0.3 mg intravitreal ranibizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates, P.A." are 9 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates, P.A.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Retina Associates, P.A., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates, P.A., 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".